✓ Translated by DotMD AI Clinical Council Source: European urology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #15041116 ↗

Randomized Controlled Trial: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil (N = 219)

Original Paper Title: “A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 219
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In the doses utilized in this study, 73% of patients preferred tadalafil with tadalafil dosing instructions for the treatment of their erectile dysfunction over sildenafil with sildenafil dosing instructions. During tadalafil therapy, 67% of patients preferred tadalafil dosing instructions over sildenafil dosing instructions.
  • Study Design & Sample: Randomized Controlled Trial published in European urology (N = 219 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in European urology (2004), this randomized controlled trial evaluating 219 human participants investigated: To assess patient preference for erectile dysfunction treatment between either sildenafil or tadalafil, each administered with their respective dosing instructions, and to evaluate preference for either sildenafil or tadalafil dosing instructions during tadalafil therapy. Key clinical takeaway: In the doses utilized in this study, 73% of patients preferred tadalafil with tadalafil dosing instructions for the treatment of their erectile dysfunction over sildenafil with sildenafil dosing instructions. During tadalafil therapy, 67% of patients preferred...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (European urology, 2004-04-15; N = 219; Rigor 88/100): In the doses utilized in this study, 73% of patients preferred tadalafil with tadalafil dosing instructions for the treatment of their erectile dysfunction over sildenafil with sildenafil dosing instructions. During tadalafil therapy, 67% of patients preferred tadalafil dosing instructions over sildenafil dosing instructions.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: tadalafil → Rx: sildenafil-citrate → Rx: sildenafil → Condition: erectile-dysfunction → Condition: combined-arterial-insufficiency-and-corporo-venous-occlusive-erectile → Condition: drug-induced-erectile-dysfunction →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 15041116: Randomized Controlled Trial: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil (N = 219)

3 of 3 Free Questions Remaining